Citations

Clear

6728 citation(s) found for "Li, Mark".

Design and validation of a biomechanics device for preclinical arthrofibrosis models
Carstens, Mason , Meißner, Nils , Weintraub, Matthew T. , Pichurin, Oksana , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Thaler, Roman , Abdel, Matthew P. , Carstens, Mason F. , Thaler, Roman , Abdel, Matthew P , Meissner, Nils , Sanchez-Sotelo, J. , Morrey, Mark E , Berry, Daniel J.

Mayo Clinic

Bone & Joint Research | June 19, 2026 | Volume: 15 | Issue: 6 | Pages: 716-725

10.1302/2046-3758.156.bjr-2025-0620.r1 | PMID 42315157 Get It

Aims Reliable assessment of joint stiffness is essential for studying arthrofibrosis in preclinical animal models. This study presents a new dedicated biomechanics device for measuring knee stiffness in mouse, rat, and rabbit models of arthrofibrosis, with the aim of validating its performance and comparing it to a previously validated device. Methods The new system integrates a torque load cell, stepper motor, and absolute encoder in a through-hole, unified configuration for precise continuous torque-angle measurement, with custom limb brackets ensuring species-specific alignment at the joint’s centre of rotation. To validate this device and compare it to a previously validated device, arthrofibrosis was induced using established models of extra-articular immobilization in mice and intra-articular violation with immobilization in rats and rabbits, followed by defined remobilization periods. Torque-angle curves were recorded ex vivo across species-specific torque ranges, and measurement variability between the new and a previous validated device was statistically compared using Brown-Forsythe’s test. Results The onset of hyperextension in contralateral limbs occurred at mean angles of 152.4° (mice), 154.4° (rats), and 152.8° (rabbits), and at maximum torque, mean flexion angles were 79.2°, 87.3°, and 140.5°, respectively. No significant differences in measurement variability were observed between devices across all species. Conclusion These findings demonstrate that our new device provides reproducible torque-angle data while maintaining the statistical robustness of the previous device and offering improved mechanical design and operational standardization. By enabling standardized, cross-species joint stiffness quantification, this platform improves cross-study comparability and strengthens the translational reliability of preclinical arthrofibrosis research. Cite this article: Bone Joint Res 2026;15(6):716–725.
Research through Evaluation for Large Language Model in Patient-Clinician Communications
Holmes, Jason, Hobson, Jared, Bennett, Alexandra, McKone, Elizabeth L. , Ebner, Daniel, Shiraishi, Satomi, Patel, Samir H. , Yu, Nathan Y. , Hallemeier, Chris L., Ball, Brooke E., Waddle, Mark, Liu, Wei, Hao, Yuexing , Holmes, Jason , Routman, David M. , Kalantari, Saleh , Ghassemi, Marzyeh

Mayo Clinic

No container title available | June 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9735115/v1 | PMID 42370275 Get It

Abstract Large Language Models (LLMs) demonstrate strong capabilities in healthcare applications. However, recruiting human evaluators to assess usability and effectiveness becomes challenging in the large-scale LLM-generated outcomes. Existing metrics are often outdated for evaluating LLM-based healthcare technologies. This paper proposes a Research through Evaluation (RtE) approach that can refine metrics and improve assessments of LLM-generated outputs. We deploy RtE in a retrospective comparative study of prostate cancer patient inquiries, comparing responses from human clinical care teams with those generated by a GPT-4-based in-basket bot. Through three rounds of co-evaluations with clinical professionals and an LLM-as-graders study with four LLMs, the RtE method shows that starting with small, iterative evaluations helps human graders adjust metrics to suit their daily practices better. Additionally, in the LLM-as-graders study, LLMs exhibit similar behavior, preferring the in-basket bot's responses over the clinical care team. Our methodology and findings demonstrate that the RtE method can enhance the transparency and robustness of evaluation metrics for LLM-generated content, with the potential to generalize to evaluations in other clinical practices.
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
What does it take to support community-engaged research in an academic medical center? A mixed-methods study of community and academic perspectives
Adsul, Prajakta , Kuhlemeier, Alena , Dugani, Sagar B. , Wallerstein, Nina , Wieland, Mark L , Sia, Irene, Dugani, Sagar B , Wallerstein, Nina , Wieland, Mark L. , Sia, Irene G. , Garovic, Vesna D.

Mayo Clinic

Journal of Clinical and Translational Science | June 17, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10771 | PMID 42534453 Get It

Abstract Introduction: There is growing focus on community-engaged research (CEnR) in the clinical and translational sciences, supportive policies, environments, and processes within academic medical centers. The purpose of this evaluation was to gather academic and community member perspectives on key actionable strategies for supporting CEnR in an academic medical center. Materials and Methods: We used a sequential mixed method design by first conducting qualitative in-depth interviews with academic leaders, investigators, and staff (total, n = 54) and focus group discussions with community members ( n = 33). Themes from these qualitative data informed the adaptation of an institutional survey that gathered perspectives from a broader group of academic and community members affiliated with the institution ( n = 85). Both qualitative and quantitative data were integrated to inform actionable strategies. Results: Survey findings revealed that the institution was perceived as committed to health equity and CEnR, but institutional respondents expressed more concerns than community members about instrumental support of the work. Interviews and focus groups highlighted the opportunity to better align research efforts with community needs through more robust CEnR infrastructure and through interface with the clinical practice to promote patient access. Academic and community members emphasized the need for authentic, sustained engagement beyond federal mandates, including financial investment, capacity-building, and fostering trust. Leaders acknowledged structural challenges, siloed efforts, and the necessity for stronger coordination to increase integration of community engagement into the institutional mission. Conclusion: Findings suggest that aligning academic leaders, researchers, staff perspectives, and community members is essential to support and promote CEnR at an institutional level.
Volume-Staged Stereotactic Radiosurgery in Pediatric Patients With Large Brain Arteriovenous Malformations: An International, Multicenter Study
Hajikarimloo, Bardia , Tos, Salem M., Ferguson, Robert , Chan, Jason W., Sneed, Penny K. , McDermott, Michael W., Seymour, Zachary , Grills, Inga, Reda, Wael A., Tawadros, Sameh R., Abdelkarim, Khaled, Emad, Reem M. , Lunsford, L. Dade, Niranjan, Ajay, Peker, S A, Samanci, Yavuz, Lee, Cheng-chia, Yang, Huai-che, Sheehan, Darrah, Sheehan, Kimball, Liscak, Roman, Chytka, Tomáš , Alzate, Juan, Kondziolka, Douglas, Moreno, Nuria Martínez , Álvarez, Roberto Martínez , Hallan, David R , Fritch, Chanju, Jareczek, Francis J., Sciscent, Bao Y., Mathieu, David, Carrier, Louis, Abdelsalam, Ahmed, Starke, Robert M., BENJAMIN, CAROLINA, Almeida, Timoteo, Singh, S.P., Lazo, Erwin, Chen, C Y, Esquenazi, Yoshua, Becerril-Gaitan, Andrea, Blanco, Angel I., Palmer, Joshua D., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg N., Peterson, Jennifer L., Chiang, Veronica , Pikis, Stylianos , Sheehan, Jason P. , Sheehan, Jason , Tos, Salem M , Mantziaris, Georgios , Shinya, Yuki , Chan, Jason , McDermott, Michael W. , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , El-Shehaby, Amr M. N. , Bin-Alamer, Othman , Lunsford, L. Dade , Niranjan, Ajay , Peker, Selçuk , Samancı, Yavuz , Lee, Cheng-chia, Yang, Huai‐Che , Sheehan, Darrah, Sheehan, Kimball , Liščák, Roman , Alzate, Juan Diego , Kondziolka, Douglas, Meng, Ying , Fritch, Chanju , Jareczek, Francis J. , Sciscent, Bao Y. , Mathieu, David , Abdelsalam, Ahmed , Starke, Robert M. , Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Lazo, Erwin , Esquenazi, Yoshua , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Lanterna, Andrea Luigi, Bowden, Greg , Warnick, Ronald E.

Mayo Clinic

Neurosurgery | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004136 | PMID 42300133 Get It

BACKGROUND AND OBJECTIVES: Pediatric large-volume brain arteriovenous malformations (AVMs) carry a substantial lifelong hemorrhage risk, neurological symptoms, and treatment morbidity. Single-session stereotactic radiosurgery (SRS) is often unsuitable due to constraints on dose-volume toxicity. Volume-staged SRS (VS-SRS) enables sequential dosing of large nidus volumes, potentially enhancing safety while maintaining efficacy. Evidence in children remains limited. We aimed to evaluate outcomes of VS-SRS for large AVMs in pediatric patients. METHODS: A multicenter retrospective cohort was assembled from 21 centers, including patients aged younger than 21 years treated with VS-SRS for AVMs >10 cm 3 . Clinical and radiological end points included obliteration, hemorrhage, and permanent symptomatic radiation-induced changes (RIC). RESULTS: A total of 103 patients were included (median age 14 years; IQR, 12-17). The median nidus volume at first stage was 18.2 cm 3 (IQR, 12.3-25.6). Median prescription dose per stage was 17 Gy (IQR, 16-18). The median clinical follow-up from the first stage was 57.5 months (IQR, 25-138). Obliteration occurred in 42 of 103 patients (40.8%), with actuarial rates of 6.9% (95% CI: 2.8-14) at 3 years and 29% (95% CI: 20-39) at 5 years. Hemorrhage occurred in 17 of 103 patients (16.5%) during follow-up, and permanent RIC was observed in 9 of 103 patients (8.7%). CONCLUSION: VS-SRS is a reasonably safe, selected option for pediatric large-volume AVMs when microsurgical or endovascular cure is not feasible or prudent. Delivering ≥17 Gy per stage while limiting each treatment volume to <15 cm 3 supports durable nidus control with acceptable toxicity. VS-SRS represents a key modality in multidisciplinary management of this historically difficult-to-treat population.
Proteomic Changes With Histological Changes 5-Years After Kidney Transplantation: Insights Into Disease Mechanisms In Obese Diabetic Recipients
Quintiliano, Artur, Alexander, M Kirillov, Charlesworth, M Cristine, Merzkani, Massini , Pandey, Akhilesh, Nagy, Sándor, Kukla, Aleksandra, Alexander, Mariam P., Charlesworth, M. Cristine , Đenić, Aleksandar , Park, Walter D. , Nagy, Sandor T, Stegall, Mark D. , Kukla, Aleksandra , Bentall, Andrew

Mayo Clinic

No container title available | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9635225/v1 Get It

Abstract Introduction: Surveillance biopsies after kidney transplantation provide an opportunity to assess early renal disease processes, including diabetic nephropathy, before clinical manifestation. This study aimed to identify proteomic alterations in renal allografts at 5 years post-transplant (5yrPT) and their associations with histologic features in diabetic/obese (DM/OB) versus non-diabetic/non-obese (nDM/nOB) recipients. Methods: We studied protocol biopsies from 17 DM/OB and 14 nDM/nOB kidney transplant recipients at Mayo Clinic (2000–2012). Laser capture microdissection followed by mass spectrometry was used for proteomic profiling. Histologic assessment included Banff and Tervaert scoring and morphometric analysis. Statistical comparisons were performed using ANOVA with Tukey post-hoc testing. Results: DM/OB recipients demonstrated greater histologic and metabolic injury at 5yrPT. Proteomic analysis identified 101 glomerular and 86 non-glomerular proteins differentially expressed between groups. Significant alterations were observed in proteins associated with mitochondrial dysfunction, including VDAC1 (fold change [FC] 2.6, p = 0.03), NDUFB9 (FC 0.15, p = 0.009), and NDUFA9 (FC 1.72, p = 0.01). Extracellular matrix remodeling proteins COL6A1, COL6A2, and COL6A3 were upregulated (FC 1.6–1.8, p < 0.05). Immune and inflammatory markers C9 (FC 1.6, p < 0.03) and TGFBI (FC 1.7, p < 0.001), as well as oxidative stress–related CLU, were increased. GGACT showed the greatest decrease (FC 0.30, p < 0.001), implicating altered energy metabolism. Conclusion: Distinct proteomic signatures at 5yrPT in DM/OB recipients highlight early mitochondrial, metabolic, immune, and extracellular matrix pathways involved in diabetic kidney disease. These changes precede clinical disease and identify candidate biomarkers and therapeutic targets to improve graft longevity.
The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease
Hove, Johan L.K. Van , Friederich, Marisa W. , Hove, Roxanne A. Van , Lee, Jessica C. , Knight, Kaz M. , Donovan, Tonia E, Silveira, Lori, Hirano, Michio, Abdenur, José E. , Cassiman, David, Cohen, Bruce H. , Elsea, Sarah H. , Enns, Gregory M., Gahl, William A, Gavrilova, Ralitza, Geddes, Gabriella C, Glamuzima, Emma E, Goldstein, Amy , Haas, Richard , Khan, Aneal , Kripps, Kimberly A. , Lehman, April, Lichter-Konecki, Uta, Morava, Eva, Rosenfeld, Jill A, Saneto, Russel P., Scaglia, Fernando , Shelkowitz, Emily , Smith, Wendy E, Soler-Alfonso, Claudia, Coster, Rudy N.A. Van, Vockley, Gerard, Wigby, Kristen, Wolfe, Lynne A. , Wortmann, Saskia B. , Van Hove, Johan L K , Ganetzky, Rebecca D , Cohen, Bruce H , Elsea, Sarah , Khan, Aneal , Larson, Austin A , Lehman, April N , Mayr, Johannes A , Scaglia, Fernando , Simon, Mariella , Smet, Joél E G , Tarnopolsky, Mark , Wolfe, Lynne A , Wortmann, Saskia , Yang, Jennifer H , Donovan, Tonia E., Ganetzky, Rebecca , Hirano, Michio , Butler, Merlin G. , Cassiman, David , Enns, Gregory M. , Gahl, William A. , Glamuzina, Emma E , Larson, Austin , Lichter‐Konecki, Uta , Morava, Éva , Peterson, James T. , Rosenfeld, Jill A. , Saneto, Russell P. , Smith, Wendy E. , Soler‐Alfonso, Claudia , Tarnopolsky, Mark A. , Vanlander, Arnaud Vincent , Vermeersch, Pieter , Wigby, Kristen M. , Yang, Jennifer H.

Mayo Clinic

No container title available | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.12.26355546 | PMID 42369463 Get It

Abstract Genome sequencing of the heterogeneous primary mitochondrial disorders (PMD) frequently reveals variants of uncertain significance that require functional tests for diagnosis, and does not identify variants in all patients. We analyzed mitochondrial enzyme assays, blue native polyacrylamide gel electrophoresis (BN-PAGE) with in-gel activity staining, complex I assembly blot, and select protein abundances in fibroblasts of a case series of 204 PMD patients divided into functional classes, in comparison to 51 controls and 53 differential diagnostic conditions. Overall, sensitivity and specificity for respiratory chain enzyme assays were 46% and 93% respectively, for BN-PAGE 40% and 98%, for complex I assembly assay 49% and 99%. The overall sensitivity of all tests was 76%, specificity 93%, with positive predictive value 96% and negative predictive value 67%. Categories with high sensitivity were isolated complex deficiencies, nuclear DNA-encoded mitochondrial protein synthesis defects, co-factor defects, and mitochondrial amino-acyl-tRNA synthetase conditions when aided by protein abundance. Mitochondrial DNA mutations and maintenance disorders showed poor sensitivities. Secondary dysfunctions were rare. A complete battery of functional tests showed strong diagnostic clinical utility in fibroblasts. One sentence summary A combination of four mitochondrial functional tests to identify or confirm suspected primary mitochondrial disease in fibroblasts had good sensitivity and excellent specificity, well beyond what was perceived using enzyme assays only.
International Delphi consensus on single‐port robotic radical prostatectomy: patient selection, surgical technique, and training
Soputro, Nicolas , Bjurlin, Marc, Srivastava, Abhishek , Umbreit, Eric, Eltemamy, Mohamed , Pak, Raymond, Gelikman, David G. , Hopson, Nicholas, Geskin, Albert , Mehrazin, Reza, VanDyke, Maia, Nguyen, Carvell, Ornstein, David, Billah, Mubashir , Russell, Christopher, Yuh, Bertram, Thong, Alan, Olivares, Ruben, Shetty, Sugandh, Shakuri‐Rad, Jaschar , Baccala, Angelo, Osinski, Thomas, Simone, Giuseppe, Lee, D Y , Baker, Mark, Ramadan, Mohammad, Mattei, Agostino , Jafri, Mohammad, Galfano, Antonio, Link, Richard E. , Lam, Po, Jones, Marklyn, Bassett, Jeffrey C. , Musi, Gennaro, Schwen, Zeyad , Beksaç, Alp Tuna , Eden, C, Miller, Scott, Gontero, P, Amparore, Daniele, Porpiglia, Francesco, Vourganti, Srinivas , Ahmed, Mutahar, Montorsi, Francesco, Perdona, Sisto, Izzo, Alessandro, Stifelman, Michael D., Crivellaro, Simone, Briganti, Alberto, Kaouk, Jihad, Autorino, Riccardo, Soputro, Nicolas A , Eltemamy, Mohamed , Gelikman, David G , Geskin, Albert , Palese, Michael , Link, Richard E , Rais‐Bahrami, Soroush , Bjurlin, Marc A. , Umbreit, Eric , Mehrazin, Reza , VanDyke, Maia , Yuh, Bertram, Thong, Alan Eih Chih , Olivares, Ruben , Baccala, Angelo A., Osinski, Thomas L. , Simone, Giuseppe , Crouzet, Sébastien , Ramadan, Mohammad Said , Porreca, Angelo , Jafri, Syed M., Galfano, Antonio , Amparore, Daniele , Ahmed, Mutahar, Montorsi, Francesco , Perdonà, Sisto , Izzo, Alessandro , STIFELMAN, MICHAEL D. , Crivellaro, Simone, Briganti, Alberto , Kaouk, Jihad , Autorino, Riccardo

Mayo Clinic

BJU International | June 16, 2026 | Volume: 138 | Issue: 3 | Pages: 456-463

10.1111/bju.70346 | PMID 42297464 Get It

Introduction The introduction of the purpose‐built single‐port (SP) robotic platform has allowed for the advent of regionalized minimally invasive surgical approaches for robotic radical prostatectomy (RARP), including the extraperitoneal and transvesical techniques. This study sought to develop a best practice consensus on the key principles, patient selection, surgical techniques, expected clinical outcomes, and learning curves pertaining to SP‐RARP. Methods A modified Delphi consensus was developed by a panel of experts, consisting of a 33‐item questionnaire, with each statement rated using a binary Likert scale (‘agree’ or ‘disagree’). The survey was distributed via email to all practicing SP‐RARP surgeons across the USA and Europe. Consensus was defined as ≥75% agreement on a given statement. Results A total of 53 surgeons participated in the Delphi Consensus across the two rounds. Of 33 statements, 28 (84.8%) reached agreement in the first round. The remaining consensus was achieved in the second round, involving 35 surgeons, and with one additional statement. The panel agreed that, although are no absolute contraindications to SP‐RARP, the preference towards specific SP‐RARP techniques should remain guided by the individual patients and surgical expertise. Although the SP extraperitoneal technique is recommended to pursue pelvic lymph node dissections, the panel agreed that transvesical SP‐RARP showed promise in promoting shorter hospital stay, faster recovery of urinary continence, and utility in patients with extensive prior abdominal surgery. Consensus was also reached on the need for a structured training pathway, with most recommending beginning with extraperitoneal SP‐RARP before advancing to the transvesical approach. Conclusion This Delphi consensus demonstrates broad agreement among experienced SP surgeons in the USA and Europe, forming the foundation for future research on the clinical utility and necessary training pathways for SP‐RARP. Nevertheless, empirical validation based on clinical data from large cohort studies remains important.
IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD
A, Prera Vilaseca, Bilodeau, Philippe-Antoine, Hellmann, Mark , Jiang, Mulan , Chen, John J., Pittock, Sean J., Levy, Michael, Flanagan, Eoin P., Levy, Michael , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Levy, Michael , Vilaseca, Andreu, Lotan, Itay , Hellmann, Mark, Pittock, Sean J. , Flanagan, Eoin P. , Kister, Ilya

Mayo Clinic

JAMA Neurology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.1850 | PMID 42295768 Get It

This case series describes multicenter experience with interleukin 6 (IL-6) receptor blockers used during attacks in aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD).